hyperaldosteronism: Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia. [ NCIT:P378 ]
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
971 |
4. Check minimum number of eventsNone |
971 |
5. Include endpointsNone |
971 |
6. Filter based on genotype QC (FinnGen only) |
971 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Hyperaldosteronismus
Similar endpoints
↥List of similar endpoints to
Hyperaldosteronism
based on the number of shared cases.
Similar with more cases:
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5523 | 2949 | 2543 |
| Only index persons | 5035 | 2705 | 2330 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.08 | 0.08 | 0.07 |
| Only index persons | 0.09 | 0.10 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 57.31 | 56.48 | 58.24 |
| Only index persons | 56.72 | 55.67 | 57.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 971 | 518 | 453 |
| Unadjusted period prevalence (%) | 0.19 | 0.18 | 0.20 |
| Median age at first event (years) | 56.90 | 54.90 | 59.18 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 859
- Matched controls
- 8588
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E26.0
ICD-10 Finland
Primary hyperaldosteronism
16384.0
323.0
666
*
C03DA01
ATC
spironolactone; oral
72.4
323.0
698
485
E26.9
ICD-10 Finland
Hyperaldosteronism, unspecified
+∞
196.6
181
*
205
Kela drug reimbursment
Chronic hypertension
7.3
155.4
533
1567
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
48.8
150.0
182
47
A12BA01
ATC
potassium chloride; oral
22.2
148.7
224
134
BC4WT
NOMESCO Finland
Selective blood sample from adrenal gland with radiological guidance
+∞
142.8
133
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
300.2
128.9
128
5
E87.6
ICD-10 Finland
Hypokalaemia
23.6
125.4
184
98
I15.2
ICD-10 Finland
Hypertension secondary to endocrine disorders
+∞
124.0
116
*
I10
ICD-10 Finland
Essential (primary) hypertension
6.8
115.9
732
3941
C08CA01
ATC
amlodipine; oral
5.2
110.0
551
2206
BC1AD
NOMESCO Finland
CT of adrenal glands
66.8
105.4
121
21
E260, I152
ICD-10 Finland
NA
+∞
88.0
83
*
C02AC05
ATC
moxonidine; oral
9.7
71.3
154
190
I15.9
ICD-10 Finland
Secondary hypertension, unspecified
46.1
58.9
72
17
C08CA13
ATC
lercanidipine; oral
4.4
54.9
233
673
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
4.1
53.9
253
802
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
58.6
47.1
55
10
C08CA02
ATC
felodipine; oral
4.9
46.7
169
409
C07AB07
ATC
bisoprolol; oral
2.8
45.1
523
3069
2551A
ICD-9 Finland
Disorders of adrenal glands, Hyperaldosteronism
+∞
42.0
40
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
23.4
41.1
59
27
E26.8
ICD-10 Finland
Other hyperaldosteronism
+∞
36.7
35
*
E26.1
ICD-10 Finland
Secondary hyperaldosteronism
+∞
35.7
34
*
C09AA02
ATC
enalapril; systemic
3.0
35.2
249
1029
C07AG02
ATC
carvedilol; oral
5.3
35.1
113
237
C08CA05
ATC
nifedipine; systemic
5.0
34.0
117
264
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
7.9
30.3
71
97
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.6
30.1
267
1253
E26
ICD-10 Finland
Hyperaldosteronism
+∞
29.3
28
*
C07AB02
ATC
metoprolol; systemic
2.7
28.9
245
1117
C09CA01
ATC
losartan; oral
2.5
28.2
271
1320
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.5
27.9
279
1387
A10BA02
ATC
metformin; oral
2.4
26.9
305
1615
103
Kela drug reimbursment
Diabetes, insulin-treated
2.4
26.3
291
1517
C09BA02
ATC
enalapril and diuretics; systemic
3.7
25.4
121
368
BCA30
NOMESCO Finland
Unilateral adrenalectomy
72.1
24.9
28
*
C09CA06
ATC
candesartan; oral
2.4
24.5
246
1212
25500
ICD-8 Finland
Diseases of adrenal glands, Aldosteronismus. Syndroma Conn
+∞
24.1
23
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
246.5
23.8
24
*
C03DB01
ATC
amiloride; oral
123.3
22.7
24
*
C08DB01
ATC
diltiazem; oral
4.2
21.8
87
226
4019X
ICD-9 Finland
Essential hypertension, Unspecified
6.4
21.7
58
96
E11
ICD-10 Finland
Type 2 diabetes mellitus
2.5
20.2
186
866
T90
ICPC
Diabetes non-insulin dependent
2.2
20.0
245
1310
C09DA01
ATC
losartan and diuretics; oral
2.8
19.1
132
519
XF602
NOMESCO Finland
Bloodpressure monitoring
13.1
19.0
33
26
C08CA03
ATC
isradipine; systemic
14.6
18.7
31
22
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.8
18.1
79
222
C03AA03
ATC
hydrochlorothiazide; oral
2.9
17.8
118
451
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
17.8
17
*
E21.0
ICD-10 Finland
Primary hyperparathyroidism
32.2
17.1
22
7
K85
ICPC
Elevated blood pressure
2.4
16.5
163
778
C02EA02
ATC
NA
4.2
16.2
63
160
C07AB08
ATC
celiprolol; oral
5.4
16.0
48
93
I11.9
ICD-10 Finland
Hypertensive heart disease without (congestive) heart failure
4.1
15.9
63
163
40199
ICD-8 Finland
Essential benign hypertension
7.2
15.8
38
55
C09CA03
ATC
valsartan; oral
2.7
15.7
114
460
I15.8
ICD-10 Finland
Other secondary hypertension
86.7
15.6
17
*
C08CA10
ATC
nilvadipine; oral
6.5
15.5
40
64
C03BA11
ATC
indapamide; oral
5.2
15.4
48
97
C02LM02
ATC
NA
8.5
15.4
33
40
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.2
15.2
182
948
BC1BD
NOMESCO Finland
Extensive CT of adrenal glands
57.7
14.8
17
*
C02DE10
ATC
NA
10.7
14.8
28
27
SPAT1262
SPAT
Handing over of treatment supplies
2.1
14.6
190
1024
C09DA06
ATC
candesartan and diuretics; oral
2.8
14.3
94
355
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.6
14.2
66
196
2533
FHL
Unilateral removal of additional egg
+∞
13.6
13
*
C03CA01
ATC
furosemide; systemic
1.9
13.5
250
1535
N18.8
ICD-10 Finland
Other chronic renal failure
5.1
13.1
41
84
C09CA07
ATC
telmisartan; oral
2.8
13.0
84
315
G47.3
ICD-10 Finland
Sleep apnoea
1.9
12.8
212
1247
C07FB02
ATC
metoprolol and felodipine; systemic
4.4
12.8
46
109
I152, E260
ICD-10 Finland
NA
+∞
12.5
12
*
207
Kela drug reimbursment
Chronic arrhythmias
2.2
12.5
143
724
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
3.4
12.1
58
177
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
3.9
11.7
48
129
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
5.9
11.4
31
54
I48
ICD-10 Finland
Atrial fibrillation and flutter
1.9
11.4
198
1182
E66.00
ICD-10 Finland
Metabolic syndrome
3.2
11.4
59
192
C02CA01
ATC
prazosin; oral
7.2
11.1
26
37
C09DB01
ATC
valsartan and amlodipine; oral
3.8
10.8
45
123
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.6
10.7
379
2795
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.7
10.6
248
1622
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
32.9
10.3
13
*
A10BH01
ATC
sitagliptin; oral
2.2
10.3
104
496
R06.0
ICD-10 Finland
Dyspnoea
1.8
10.2
214
1353
C07AB03
ATC
atenolol; systemic
2.8
10.1
67
256
B01AA03
ATC
warfarin; systemic
1.9
9.9
173
1027
XF400
NOMESCO Finland
ECG with 12 standard connections
1.9
9.9
151
858
C02DE02
ATC
NA
5.8
9.9
27
48
A11CC03
ATC
alfacalcidol; systemic
5.2
9.8
29
57
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.8
9.6
182
1113
H02AB09
ATC
hydrocortisone; systemic
6.5
9.6
24
38
C02EA03
ATC
NA
7.3
9.5
22
31
TFP20
NOMESCO Finland
Cardiodefibrillation
2.4
9.4
79
345
PC5CG
NOMESCO Finland
Extensive MRI examination of kidney vasculature with high intensity magnet
30.4
9.4
12
*
A10BH05
ATC
linagliptin; oral
2.9
9.3
56
203
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
9.6
9.3
18
19
C08DA01
ATC
verapamil; systemic
3.2
9.2
47
152
C07BB07
ATC
bisoprolol and thiazides; systemic
3.1
9.0
49
167
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
6.0
8.8
23
39
C09DA07
ATC
telmisartan and diuretics; oral
2.9
8.7
51
182
J45.9
ICD-10 Finland
Asthma, unspecified
1.8
8.5
147
868
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
2.9
8.4
49
174
H05BX01
ATC
cinacalcet; oral
+∞
8.3
8
*
C07AB04
ATC
acebutolol; systemic
5.6
8.3
23
42
C07AB05
ATC
betaxolol; oral
3.9
8.3
33
88
N02BE01
ATC
paracetamol; systemic, rectal
1.7
8.2
729
6565
C10AA01
ATC
simvastatin; oral
1.5
8.2
371
2849
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.6
7.9
259
1836
WX408
NOMESCO Finland
General anesthesy, balanced
1.6
7.8
229
1575
XF404
NOMESCO Finland
Ambulatory ECG
2.1
7.8
92
474
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
2.1
7.8
91
463
A12AA04
ATC
calcium carbonate; oral
6.4
7.7
19
30
I50.9
ICD-10 Finland
Heart failure, unspecified
2.0
7.7
103
557
R4110
NOMESCO Finland
Physiotherapy
1.6
7.5
221
1523
J01MA02
ATC
ciprofloxacin; systemic
1.5
7.4
313
2350
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.1
7.3
86
438
I12.0
ICD-10 Finland
Hypertensive renal disease with renal failure
8.5
7.3
15
18
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
7.3
7
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
7.3
7
*
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
7.3
7
*
O10.0
ICD-10 Finland
Pre-existing essential hypertension complicating pregnancy, childbirth and the puerperium
5.2
7.3
21
41
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
2.6
7.3
50
197
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.1
7.2
77
378
C09CA08
ATC
olmesartan medoxomil; oral
4.7
7.2
23
50
A10BJ06
ATC
semaglutide; parenteral
3.1
7.2
37
122
C09AA03
ATC
lisinopril; oral
2.7
7.2
46
174
I15
ICD-10 Finland
Secondary hypertension
30.3
7.2
9
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
30.3
7.2
9
*
A06AC01
ATC
ispaghula (psylla seeds); oral
1.6
7.0
194
1313
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
10.1
7.0
13
13
C07AB12
ATC
nebivolol; oral
3.2
7.0
34
108
A10BK03
ATC
empagliflozin; oral
2.1
6.9
73
359
TPH04
NOMESCO Finland
Cathetrisation of vein
1.6
6.9
174
1150
R04.0
ICD-10 Finland
Epistaxis
2.2
6.9
65
303
WX110
NOMESCO Finland
Local anesthesy
1.5
6.9
547
4666
C09DA03
ATC
valsartan and diuretics; oral
2.5
6.8
52
219
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
40.4
6.8
8
*
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.8
6.8
124
747
A10BB12
ATC
glimepiride; oral
2.2
6.7
64
298
B01AF02
ATC
apixaban; oral
2.0
6.7
86
459
C09DX01
ATC
valsartan, amlodipine and hydrochlorothiazide; oral
3.9
6.6
25
65
C02DE04
ATC
NA
3.4
6.6
30
91
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.8
6.5
122
738
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
1.8
6.5
108
632
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.5
6.4
274
2048
M04AA01
ATC
allopurinol; systemic
1.8
6.4
109
638
R07.4
ICD-10 Finland
Chest pain, unspecified
1.5
6.4
218
1548
N02AX02
ATC
tramadol; systemic, rectal
1.5
6.4
344
2700
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
5.6
6.3
17
31
N05BA04
ATC
oxazepam; oral
1.6
6.3
194
1345
D350, E260
ICD-10 Finland
NA
+∞
6.3
6
*
E260, D350
ICD-10 Finland
NA
+∞
6.3
6
*
A10AE04
ATC
insulin glargine; parenteral
2.0
6.2
82
437
C02EA06
ATC
NA
26.9
6.2
8
*
J01MA06
ATC
norfloxacin; oral
1.8
6.2
109
644
R60.0
ICD-10 Finland
Localized oedema
1.9
6.2
95
536
N17.9
ICD-10 Finland
Acute renal failure, unspecified
2.8
6.2
36
130
C02DE12
ATC
NA
7.7
6.1
13
17
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
7.7
6.1
13
17
R03BA02
ATC
budesonide; inhalant
1.7
6.1
134
850
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
6.1
100
581
C09BA03
ATC
lisinopril and diuretics; oral
3.4
6.1
27
81
C03EB01
ATC
furosemide and potassium-sparing agents; systemic
2.8
6.1
36
132
K86
ICPC
Hypertension uncomplicated
1.8
6.0
104
611
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
4.2
6.0
21
51
E66.9
ICD-10 Finland
Obesity, unspecified
3.1
6.0
31
104
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
288
87
46.64
307.65
3.0
1.2
537.2
304.2
pmol/l
4.04
248
73
169
90
22.52
220.06
1.3
1.2
0.6
0.6
nmol/l
0.46
159
83
145
77
21.96
188.37
1.3
1.2
—
—
nmol/l
—
0
0
81
24
36.73
128.72
1.7
1.1
731.7
368.1
pmol/l
2.46
59
16
275
691
5.16
105.66
2.4
2.0
324.9
373.8
nmol/l
2.97
261
637
72
30
25.84
102.14
1.6
1.4
3.7
1.1
nmol/l
1.08
63
25
369
1325
3.88
86.21
3.0
3.4
0.8
0.8
mmol/l
0.36
347
1251
675
4065
3.17
60.45
9.5
6.7
1.2
1.2
mmol/l
0.46
570
3455
623
3704
2.90
54.89
9.0
6.0
1.2
1.2
mmol/l
0.47
591
3361
490
2637
2.73
51.32
4.9
3.9
15.0
8.5
mg/mmol
1.82
324
1683
475
2609
2.61
46.40
3.8
3.1
7.2
7.7
mmol/l
1.54
408
2183
257
1047
2.98
44.93
8.8
5.7
1.1
1.0
mmol/l
0.17
242
969
173
557
3.56
44.77
5.8
3.4
109.9
83.1
ng/l
2.94
156
491
242
1071
2.68
35.23
6.8
7.5
104.2
104.3
mmol/l
0.10
242
1045
401
2300
2.27
32.44
3.7
3.1
0.5
0.5
e6/l
0.03
305
1745
539
3522
2.19
31.10
5.7
4.8
36.1
35.4
g/l
2.84
500
3289
311
1736
2.16
25.71
3.0
2.5
3.9
5.6
e6/l
1.89
275
1533
169
726
2.61
25.46
10.9
7.2
11.3
9.8
mmol/l
1.50
160
694
112
391
3.11
24.84
5.6
4.0
24.0
24.2
mmol/l
0.30
101
353
654
4856
2.06
24.05
6.3
5.0
7.1
6.7
mmol/l
3.29
624
4573
170
771
2.46
22.68
5.2
3.7
1.8
2.1
mmol/l
0.35
143
610
480
3256
1.94
22.26
2.9
2.1
76.0
77.1
nmol/l
0.38
440
2881
74
214
3.66
22.09
3.0
3.7
1.7
1.6
mg/l
0.18
65
196
169
780
2.41
21.64
5.3
3.6
5.9
5.8
kpa
0.17
164
755
784
6340
2.23
21.53
8.7
7.6
76.1
78.5
u/l
1.08
761
5947
349
2169
1.95
20.61
3.2
2.7
4660.6
7412.4
umol/l
0.50
295
1875
884
7658
2.72
18.63
8.4
5.8
41.7
40.0
mmol/mol
5.22
834
7103
201
1080
2.09
17.51
4.5
2.5
23.4
22.9
%
0.20
178
926
407
2768
1.81
17.40
3.5
3.4
2.4
2.3
mmol/l
0.30
361
2411
752
6169
1.97
17.17
4.8
3.8
15.0
14.8
pmol/l
1.39
690
5591
210
1159
2.04
16.96
4.3
2.4
2.3
2.3
g/l
0.06
197
1075
222
1255
2.00
16.74
4.2
2.5
13.1
13.0
umol/l
0.11
210
1161
797
6709
2.05
16.37
25.5
18.0
13.7
13.7
%
0.05
787
6577
570
4331
1.77
16.25
5.6
6.4
11.9
11.5
umol/l
0.24
540
4125
533
3978
1.75
16.13
5.8
4.9
0.0
0.0
estimate
0.50
135
724
605
4695
1.77
15.83
8.3
9.3
4.4
4.1
e9/l
2.86
527
4113
365
2461
1.77
15.65
3.5
3.0
1778.7
1195.0
ng/l
1.28
311
2120
854
7416
2.26
15.57
5.9
4.6
1.9
1.9
mu/l
0.18
797
6760
136
656
2.25
15.46
6.2
3.8
1.2
1.2
mmol/l
0.44
126
570
260
1592
1.86
15.27
4.3
4.0
647.0
341.9
ng/l
0.25
215
1271
528
3976
1.72
15.07
4.5
3.6
0.0
0.0
estimate
0.00
135
721
533
4029
1.72
14.95
4.5
3.6
0.0
0.0
estimate
0.50
126
701
226
1334
1.90
14.82
3.1
3.0
1.9
2.2
e6/l
0.25
115
742
239
1437
1.88
14.80
3.0
2.7
0.8
1.1
e6/l
1.62
128
841
874
7720
2.32
14.31
24.0
13.4
73.5
79.8
ml/min/173m2
12.03
781
6385
726
6056
1.79
13.59
4.8
4.0
13.7
12.4
mm/h
1.21
685
5596
927
8455
3.13
13.46
30.9
16.9
139.5
139.7
mmol/l
1.30
916
8229
130
651
2.15
13.41
4.3
2.9
5.0
4.5
kpa
1.39
124
627
32
72
4.56
13.38
2.2
2.5
—
—
—
0
0
378
2675
1.68
13.02
2.9
3.3
30.9
32.5
u/l
0.29
357
2544
927
8477
3.06
12.95
32.3
17.0
3.9
4.0
mmol/l
15.39
916
8245
98
445
2.34
12.79
11.1
11.4
24.5
24.6
mmol/l
0.02
92
423
897
8096
2.42
12.49
21.0
14.6
21.4
24.6
mg/l
2.44
765
6457
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
67
260
2.69
12.17
2.6
2.5
0.3
0.4
u/ml
0.23
36
146
183
1080
1.86
11.76
32.8
25.5
1.5
1.3
inr
0.69
18
144
325
2263
1.66
11.62
1.7
1.7
1.6
1.4
mmol/l
3.20
277
1902
142
777
1.97
11.46
2.7
2.6
31.5
41.9
u/l
1.00
120
669
650
5378
1.63
11.25
5.7
4.5
579.0
3096.2
e6/l
—
6
91
129
688
2.01
11.18
2.5
3.0
66.1
66.7
g/l
0.40
115
634
885
8008
2.19
11.15
6.1
4.7
6.4
6.0
mmol/l
9.94
828
7299
427
3205
1.59
11.11
4.6
3.7
42.7
50.5
ng/l
0.22
321
2291
91
425
2.26
11.11
3.2
3.2
4.3
4.5
pmol/l
1.81
82
378
447
3394
1.59
11.06
2.2
2.0
93.5
95.2
pmol/l
0.32
235
1776
159
918
1.88
10.90
2.6
4.3
234.9
252.1
u/l
0.79
143
869
101
497
2.15
10.84
4.5
3.7
2.3
1.9
mmol/l
0.37
70
384
114
589
2.06
10.77
2.5
2.1
11.7
12.8
nmol/l
0.24
98
523
105
528
2.11
10.66
4.6
3.7
5.1
5.2
kpa
0.41
97
498
165
974
1.84
10.52
8.5
8.1
12.1
12.1
kpa
0.01
159
935
165
974
1.84
10.52
8.5
8.1
5.3
5.1
kpa
0.93
159
934
15
22
6.91
9.75
1.0
1.1
0.6
0.7
umol/24h
—
7
13
232
1543
1.66
9.64
3.4
3.1
2.4
2.5
mmol/l
0.24
201
1358
161
978
1.77
9.28
8.6
8.1
1.3
1.3
mmol/l
0.05
133
764
343
2528
1.55
9.21
2.3
2.2
186.0
234.6
u/l
0.63
325
2386
46
172
2.76
9.01
3.0
2.6
18.3
16.0
%
2.94
30
96
46
177
2.68
8.54
1.8
2.4
138.0
129.4
g/l
1.28
35
133
98
528
1.95
8.22
3.9
3.4
132.5
127.9
g/l
1.11
98
519
433
3416
1.48
8.15
4.1
2.7
153.8
137.2
ug/l
0.92
402
3150
256
1809
1.56
8.12
1.8
1.7
0.9
1.2
mg/l
1.37
193
1390
60
269
2.31
8.09
2.4
3.9
36.0
43.7
mg/l
0.28
49
219
480
3882
1.47
7.87
4.2
4.1
—
—
—
0
0
59
269
2.27
7.66
2.4
3.9
42.5
75.4
mg/l
0.76
48
218
342
2601
1.49
7.60
2.8
2.6
58.1
57.3
u/l
0.13
313
2410
291
2149
1.51
7.44
5.0
3.9
0.0
0.0
estimate
0.09
125
694
807
7301
1.62
7.33
24.1
15.9
40.1
39.9
%
0.30
569
5141
275
2014
1.51
7.29
1.7
1.5
18.3
20.8
nmol/l
2.46
249
1702
49
213
2.37
7.10
2.7
2.5
139.2
73.2
ug/min
0.53
28
130
889
8278
1.88
6.99
6.3
5.0
2.6
2.7
mmol/l
7.89
822
7607
389
3071
1.44
6.98
4.9
3.8
—
—
—
0
0
60
289
2.15
6.84
2.4
2.6
10.4
10.6
g/l
0.14
52
251
274
2040
1.48
6.60
2.5
2.1
2.9
3.1
mg/l
0.38
234
1743
920
8688
2.12
6.60
13.7
10.6
33.2
26.3
u/l
0.73
899
8367
135
860
1.66
6.47
4.9
3.3
—
—
—
0
0
845
7794
1.65
6.38
4.9
4.0
1.5
1.3
mmol/l
10.45
773
7113
144
939
1.63
6.29
2.8
2.7
6.7
8.5
umol/l
0.58
120
824
868
8075
1.71
6.17
5.6
4.5
1.3
1.5
mmol/l
23.35
800
7411
35
139
2.57
6.17
2.3
1.6
188.5
216.3
pmol/l
0.90
30
125
61
310
2.03
6.07
2.4
2.5
3.7
3.8
g/l
0.15
42
228
90
521
1.80
6.07
1.6
1.7
—
—
—
0
0
42
184
2.34
6.02
1.3
1.6
1.4
0.8
nmol/l
1.14
30
154
61
311
2.03
6.01
2.4
2.5
7.5
7.5
g/l
0.11
43
238
61
311
2.03
6.01
2.4
2.5
—
—
—
0
0
70
375
1.93
6.00
1.7
2.0
1.6
1.6
g/l
0.01
60
324
196
1387
1.52
5.99
1.9
1.9
—
—
—
0
0
48
224
2.20
5.94
2.3
2.7
0.0
0.0
g/l
0.00
43
209
871
8132
1.69
5.83
5.6
4.5
4.4
4.6
mmol/l
12.67
812
7513
92
543
1.77
5.81
12.4
10.3
0.7
0.7
%
0.16
92
538
65
345
1.95
5.73
2.2
2.1
43.0
39.7
u/l
0.72
55
306
613
5367
1.39
5.52
3.4
3.1
49.9
50.6
u/l
0.08
584
4990
91
545
1.74
5.48
12.3
10.1
1.2
1.3
%
0.95
91
540
226
1674
1.46
5.47
1.2
1.2
1.0
1.7
u/ml
0.82
60
454
49
239
2.11
5.45
2.3
2.7
0.0
0.0
g/l
0.00
44
223
50
248
2.07
5.33
2.4
2.6
36.4
37.4
g/l
0.59
43
217
142
976
1.53
4.93
1.6
1.8
—
—
—
0
0
118
791
1.56
4.58
2.1
2.2
0.2
0.2
g/l
1.16
106
739
51
270
1.94
4.58
2.3
2.9
0.3
1.4
g/l
2.51
44
241
141
988
1.50
4.47
1.7
1.8
—
—
—
0
0
16
50
3.24
4.35
1.3
1.1
90.2
77.9
u/l
0.38
11
45
22
86
2.59
4.07
1.2
1.2
50.5
53.0
u/l
0.11
12
61
15
48
3.16
3.94
1.3
1.1
21.4
16.1
u/l
—
10
42
52
294
1.81
3.86
1.3
1.6
—
155.4
—
0
13
254
2029
1.34
3.79
2.3
2.3
—
—
—
0
0
51
290
1.80
3.72
2.4
2.6
3.2
3.2
g/l
0.18
43
232
27
123
2.23
3.63
1.0
1.1
4.0
30.0
iu/ml
—
6
27
27
125
2.19
3.50
1.3
1.3
—
—
—
0
0
222
1773
1.33
3.28
3.5
3.1
0.8
0.7
ug/l
0.20
158
1161
197
1553
1.34
3.17
2.0
1.7
1210.5
1197.3
nmol/l
0.06
150
1172
930
9013
1.75
3.17
32.4
21.6
137.3
135.5
g/l
3.07
923
8869
41
230
1.82
3.16
2.2
2.8
3.7
3.7
g/l
0.10
41
219
105
748
1.45
3.09
2.4
2.4
12.5
7.0
ug/l
0.54
88
667
533
4781
1.25
3.06
2.8
2.8
—
—
—
0
0
33
177
1.89
2.94
1.4
1.4
—
—
—
0
0
33
177
1.89
2.94
1.4
1.4
—
—
—
0
0
52
324
1.64
2.81
6.4
4.1
25.2
25.0
mmol/l
0.20
46
313
93
661
1.45
2.78
2.9
2.8
56.6
66.6
ml/min/173m2
1.84
56
262
7
14
5.03
2.73
1.0
1.2
1.9
1.9
umol/24h
—
7
14
38
219
1.77
2.72
1.3
1.3
—
—
—
0
0
6
10
6.03
2.70
1.3
1.0
—
—
—
0
0
216
1767
1.29
2.64
1.9
1.7
113636795.2
30319943.9
pmol/l
0.45
176
1471
83
587
1.45
2.56
1.6
1.7
—
—
—
0
0
40
241
1.69
2.48
1.2
1.2
—
—
—
0
0
40
241
1.69
2.48
1.2
1.2
—
—
—
0
0
33
188
1.78
2.48
3.2
3.1
0.8
0.8
nmol/l
0.01
27
152
8
21
3.83
2.46
1.8
1.6
—
—
—
0
0
39
234
1.69
2.45
2.6
1.6
—
—
—
0
0
21
103
2.06
2.43
1.2
1.0
—
—
—
0
0
37
220
1.71
2.41
1.6
2.1
12.4
12.1
mg/l
0.07
30
203
28
153
1.85
2.40
3.3
3.3
4.0
4.2
e9/l
0.27
28
153
13
52
2.52
2.36
1.8
1.5
1.7
9.2
u/l
—
7
25
13
53
2.47
2.28
1.1
1.2
—
—
—
0
0
22
113
1.97
2.26
1.3
1.2
1.3
2.3
u/ml
—
7
35
5
9
5.58
2.21
10.0
6.3
5.6
6.6
mmol/l
—
5
9
29
165
1.78
2.21
1.6
2.1
2813.8
3533.8
u/l
—
5
58
28
158
1.80
2.19
3.5
3.6
57.0
57.8
%
0.10
28
158
20
101
2.00
2.16
1.3
2.3
33.3
32.6
pg
0.24
20
101
7
19
3.70
2.15
1.0
1.0
—
—
—
0
0
69
493
1.43
2.06
1.5
1.5
—
—
—
0
0
6
15
4.02
2.04
1.2
1.2
100.8
88.3
%
—
6
15
6
15
4.02
2.04
1.2
1.2
—
—
—
0
0
69
496
1.42
2.00
1.2
1.2
136.9
141.5
iu/ml
0.03
22
197
37
233
1.61
1.98
1.6
1.6
0.0
0.1
iu/ml
—
9
46
21
112
1.89
1.97
1.3
1.2
3.0
4.2
u/ml
—
8
43
32
196
1.65
1.92
2.1
3.4
30.0
33.3
umol/l
0.45
26
167
49
333
1.50
1.90
3.8
3.5
2502.4
4314.1
u/ml
0.19
42
283
15
73
2.07
1.81
1.1
1.1
—
—
—
0
0
9
35
2.59
1.80
1.2
1.1
—
—
—
0
0
50
347
1.46
1.77
1.8
1.9
1.3
2.3
ug/l
0.49
43
312
31
193
1.63
1.76
1.5
1.8
5.2
5.6
iu/l
—
10
59
39
257
1.54
1.76
1.4
1.4
286.8
280.8
ug/g
0.05
22
152
10
41
2.45
1.76
1.0
1.1
—
—
—
0
0
165
1373
1.24
1.75
1.3
1.3
40.4
33.6
iu/ml
0.18
46
441
12
54
2.24
1.74
1.2
1.4
14.8
13.2
u/l
0.18
12
49
157
1305
1.24
1.68
1.3
1.3
19.1
11.7
u/ml
0.31
52
491
19
104
1.84
1.68
1.1
1.1
—
—
—
0
0
13
62
2.11
1.66
1.2
1.3
12.4
11.9
mmol/l
—
8
16
16
83
1.94
1.65
4.3
2.3
13.6
13.1
%
0.89
16
83
14
69
2.04
1.65
1.0
1.1
—
—
—
0
0
277
2441
1.19
1.64
4.7
4.3
23.3
20.9
%
1.73
143
1165
146
1210
1.24
1.61
1.3
1.5
—
—
—
0
0
29
183
1.60
1.59
1.4
1.5
—
—
—
0
0
7
26
2.70
1.58
1.6
1.3
45.1
62.0
ug/l
—
7
26
37
249
1.51
1.54
1.9
1.7
—
—
—
0
0
8
33
2.44
1.54
2.3
2.2
—
—
—
0
0
0
43
0.00
1.52
0.0
1.3
—
—
—
0
0
9
38
2.38
1.46
1.9
3.0
449.4
1148.2
u/ml
—
9
38
32
212
1.53
1.45
1.7
1.3
—
—
—
0
0
13
66
1.98
1.44
1.2
1.9
—
—
—
0
0
333
3008
1.16
1.44
5.6
5.0
2.5
2.4
ug/l
0.10
307
2698
12
60
2.01
1.38
1.1
1.2
—
—
—
0
0
12
60
2.01
1.38
1.1
1.2
—
—
—
0
0
12
61
1.98
1.33
1.1
1.1
—
—
—
0
0
12
61
1.98
1.33
1.1
1.1
—
—
—
0
0
12
61
1.98
1.33
1.1
1.1
—
—
—
0
0
41
296
1.40
1.24
2.0
1.8
—
—
—
0
0
21
131
1.62
1.24
2.3
1.4
124.1
110.3
u/ml
—
7
24
31
212
1.48
1.24
1.8
1.6
—
—
—
0
0
49
367
1.35
1.20
1.1
1.0
—
—
—
0
0
28
189
1.50
1.20
2.1
1.5
11.2
26.8
e6/l
0.42
21
145
28
189
1.50
1.20
2.2
1.6
5100.2
164.8
e6/l
0.64
22
148
50
654
0.75
1.17
1.6
1.7
—
—
—
0
0
8
40
2.01
1.12
1.3
1.3
6.0
6.4
mmol/l
—
8
40
19
121
1.58
1.06
1.2
1.7
—
—
—
0
0
50
385
1.31
1.05
1.2
1.3
—
—
—
0
0
29
204
1.43
1.04
1.4
1.8
5723.9
16391.8
e6/l
1.77
16
154
9
47
1.92
1.02
1.1
1.7
4.4
6.7
u/l
—
9
37
43
326
1.33
1.00
2.2
1.9
—
—
—
0
0
29
206
1.42
0.99
1.1
1.1
—
—
—
0
0
15
93
1.62
0.94
1.2
1.9
—
—
—
0
0
6
28
2.15
0.91
1.2
1.3
106.0
109.5
%
—
6
22
14
219
0.63
0.91
1.5
1.4
—
—
—
0
0
33
245
1.36
0.90
2.1
1.6
—
—
—
0
0
29
211
1.39
0.89
1.2
1.3
—
—
—
0
0
26
187
1.40
0.86
1.2
1.4
—
—
—
0
0
8
45
1.78
0.84
1.5
1.4
—
—
—
0
0
8
45
1.78
0.84
1.5
1.4
—
—
—
0
0
112
972
1.17
0.83
1.8
1.8
1.5
1.5
%
0.17
96
840
105
907
1.18
0.82
3.5
4.3
11.2
29.1
ug/l
1.02
78
763
37
286
1.31
0.79
1.9
2.8
—
—
—
0
0
9
53
1.70
0.75
1.0
1.2
—
—
—
0
0
9
53
1.70
0.75
1.0
1.2
—
—
—
0
0
5
25
2.01
0.72
1.2
1.3
7.9
9.4
ug/l
—
5
25
28
211
1.34
0.72
1.0
1.1
1.2
5.1
u/ml
—
5
23
14
93
1.51
0.69
2.5
3.9
—
—
—
0
0
22
161
1.37
0.68
1.3
1.2
—
7.4
—
0
12
9
59
1.53
0.68
2.1
1.8
—
—
—
0
0
13
86
1.52
0.66
4.8
2.7
—
—
—
0
0
23
171
1.35
0.66
1.3
1.2
—
—
—
0
0
91
1034
0.87
0.62
14.4
6.9
—
—
—
0
0
8
49
1.64
0.62
1.0
1.0
—
—
—
0
0
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
6
35
1.72
0.57
1.3
2.1
74.5
50.8
umol/l
—
6
26
8
54
1.49
0.57
1.3
1.8
—
—
—
0
0
11
73
1.51
0.56
2.0
1.6
—
—
—
0
0
28
221
1.27
0.56
1.3
1.2
—
2.5
—
0
7
16
116
1.39
0.54
1.0
1.1
—
—
—
0
0
9
63
1.43
0.52
1.0
1.2
—
—
—
0
0
191
1775
1.09
0.51
5.4
3.9
1.0
1.0
kg/l
0.23
44
244
19
145
1.32
0.49
1.2
1.8
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
45
1.56
0.49
1.0
1.2
—
—
—
0
0
7
46
1.53
0.48
1.3
1.9
—
—
—
0
0
7
46
1.53
0.48
1.3
1.9
—
—
—
0
0
74
655
1.14
0.48
2.2
1.9
—
—
—
0
0
118
1078
1.11
0.46
1.4
1.4
—
—
—
0
0
7
49
1.43
0.46
2.3
1.9
—
—
—
0
0
19
147
1.30
0.45
1.7
1.1
—
—
—
0
0
15
113
1.33
0.43
1.3
1.5
—
—
—
0
0
6
93
0.64
0.42
1.3
1.7
—
—
—
0
0
5
32
1.57
0.42
1.0
1.0
—
—
—
0
0
8
57
1.41
0.42
1.1
1.5
1.0
1.0
g/l
—
8
57
14
105
1.34
0.41
1.0
1.1
—
—
—
0
0
25
304
0.82
0.41
2.6
1.9
—
—
—
0
0
15
114
1.32
0.41
1.3
1.5
—
—
—
0
0
15
114
1.32
0.41
1.3
1.5
—
—
—
0
0
0
17
0.00
0.40
0.0
1.4
—
—
—
0
0
12
88
1.37
0.40
1.4
1.4
202822.9
38147.2
e6/l
—
7
52
30
251
1.20
0.39
2.0
2.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
2.1
—
2.1
—
0
8
15
115
1.31
0.39
1.3
1.5
—
—
—
0
0
15
115
1.31
0.39
1.3
1.5
—
—
—
0
0
21
169
1.25
0.39
2.1
1.6
—
—
—
0
0
9
67
1.35
0.38
1.0
1.0
—
—
—
0
0
94
1026
0.91
0.38
5.8
4.6
29.8
32.3
%
1.58
64
679
9
68
1.33
0.37
1.1
1.3
—
—
—
0
0
27
225
1.21
0.37
1.5
1.4
—
—
—
0
0
9
69
1.31
0.37
2.3
1.7
—
—
—
0
0
6
42
1.43
0.35
1.0
1.1
—
—
—
0
0
16
126
1.27
0.35
1.9
1.7
—
—
—
0
0
24
200
1.21
0.34
1.2
1.7
—
—
—
0
0
6
46
1.31
0.33
1.2
2.2
—
—
—
0
0
6
46
1.31
0.33
1.5
3.4
—
—
—
0
0
6
47
1.28
0.32
1.2
1.1
—
—
—
0
0
20
240
0.83
0.31
2.7
1.8
—
—
—
0
0
27
231
1.17
0.30
1.2
1.4
—
—
—
0
0
11
141
0.78
0.29
1.2
1.1
—
—
—
0
0
8
109
0.73
0.29
1.4
1.4
—
—
—
0
0
8
109
0.73
0.29
1.4
1.4
—
—
—
0
0
7
57
1.23
0.29
1.6
1.5
—
—
—
0
0
8
110
0.73
0.29
1.4
1.4
—
—
—
0
0
8
110
0.73
0.29
1.4
1.4
—
—
—
0
0
12
94
1.28
0.28
1.1
1.3
—
—
—
0
0
9
116
0.77
0.27
1.4
1.5
—
—
—
0
0
14
113
1.24
0.26
1.9
1.6
—
—
—
0
0
22
188
1.17
0.25
1.1
1.3
81.4
242.0
miu/ml
—
8
85
6
85
0.70
0.24
1.2
1.8
—
—
—
0
0
14
115
1.22
0.23
1.3
1.5
—
—
—
0
0
16
189
0.84
0.22
1.6
1.6
—
—
—
0
0
14
116
1.21
0.22
1.1
1.7
—
—
—
0
0
5
41
1.22
0.22
3.6
1.3
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
8
102
0.78
0.21
1.0
1.1
1.5
1.5
g/l
—
8
94
5
43
1.16
0.21
1.8
1.2
3.3
2.4
ug/l
—
5
33
5
43
1.16
0.21
1.2
1.2
—
—
—
0
0
64
596
1.08
0.20
2.0
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
6
50
1.20
0.19
1.3
1.9
0.2
0.2
e9/l
—
6
44
27
241
1.12
0.19
1.2
1.3
—
—
—
0
0
6
52
1.15
0.19
1.3
1.9
382.7
643.7
e6/l
—
6
44
13
109
1.20
0.18
1.2
1.7
—
—
—
0
0
7
60
1.17
0.18
1.1
1.2
—
—
—
0
0
7
63
1.11
0.17
1.0
1.2
—
—
—
0
0
6
80
0.75
0.15
1.7
1.5
—
—
—
0
0
17
188
0.90
0.11
3.2
3.8
23.3
27.3
mg/l
—
7
118
6
71
0.84
0.07
1.2
1.4
—
—
—
0
0
8
75
1.07
0.07
1.1
1.6
—
—
—
0
0
8
75
1.07
0.07
1.1
1.6
—
—
—
0
0
8
75
1.07
0.07
1.1
1.6
—
—
—
0
0
21
196
1.07
0.07
1.2
1.7
—
—
—
0
0
9
86
1.05
0.07
1.1
1.1
—
—
—
0
0
8
90
0.89
0.06
1.1
1.1
—
—
—
0
0
10
111
0.90
0.06
4.7
2.6
104.4
105.5
mmol/l
—
10
111
13
119
1.09
0.06
2.7
2.8
—
859.1
—
0
9
13
124
1.05
0.00
1.2
1.6
—
—
—
0
0
12
118
1.02
0.00
1.6
1.5
—
—
—
0
0
15
145
1.04
0.00
1.3
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
12.3
—
0
8
0
5
0.00
0.00
0.0
1.6
—
2.6
—
0
5
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
7
77
0.91
0.00
1.7
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
7
73
0.96
0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_HYPERALDO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALDO | 1.424 [1.23, 1.65] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.123 |
During the follow-up period (1.1.1998 — 31.12.2019), 414 out of 2277 females with E4_HYPERALDO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_HYPERALDO | 1.218 [1.05, 1.41] | 0.009 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 357 out of 2005 males with E4_HYPERALDO died.
Mortality risk
Mortality risk for people of age
years, who have E4_HYPERALDO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.081% | 0.205% |
| 5 | 0.68% | 1.319% |
| 10 | 2.096% | 3.219% |
| 15 | 3.905% | 6.3% |
| 20 | 7.079% | 10.338% |
Relationships between endpoints
↥Index endpoint: E4_HYPERALDO – Hyperaldosteronism
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data